Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.15
SLXP's Cash to Debt is ranked lower than
51% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. SLXP: 0.15 )
SLXP' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.15

Equity to Asset 0.11
SLXP's Equity to Asset is ranked lower than
53% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SLXP: 0.11 )
SLXP' s 10-Year Equity to Asset Range
Min: 0.11   Max: 0.9
Current: 0.11

0.11
0.9
Interest Coverage 4.41
SLXP's Interest Coverage is ranked higher than
52% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. SLXP: 4.41 )
SLXP' s 10-Year Interest Coverage Range
Min: 3.1   Max: 9999.99
Current: 4.41

3.1
9999.99
F-Score: 5
Z-Score: 1.65
M-Score: -1.88
WACC vs ROIC
5.81%
0.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 1.94
SLXP's Operating margin (%) is ranked higher than
64% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. SLXP: 1.94 )
SLXP' s 10-Year Operating margin (%) Range
Min: -511.93   Max: 29.1
Current: 1.94

-511.93
29.1
Net-margin (%) -5.58
SLXP's Net-margin (%) is ranked higher than
58% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. SLXP: -5.58 )
SLXP' s 10-Year Net-margin (%) Range
Min: -475.24   Max: 16.17
Current: -5.58

-475.24
16.17
ROE (%) -11.33
SLXP's ROE (%) is ranked higher than
57% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. SLXP: -11.33 )
SLXP' s 10-Year ROE (%) Range
Min: -102   Max: 21.98
Current: -11.33

-102
21.98
ROA (%) -1.98
SLXP's ROA (%) is ranked higher than
61% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. SLXP: -1.98 )
SLXP' s 10-Year ROA (%) Range
Min: -77.4   Max: 10.41
Current: -1.98

-77.4
10.41
ROC (Joel Greenblatt) (%) 5.47
SLXP's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. SLXP: 5.47 )
SLXP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7190.09   Max: 161.23
Current: 5.47

-7190.09
161.23
Revenue Growth (3Y)(%) 34.20
SLXP's Revenue Growth (3Y)(%) is ranked higher than
96% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. SLXP: 34.20 )
SLXP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2   Max: 112.5
Current: 34.2

-2
112.5
EBITDA Growth (3Y)(%) 207.90
SLXP's EBITDA Growth (3Y)(%) is ranked higher than
100% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. SLXP: 207.90 )
SLXP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.2   Max: 207.9
Current: 207.9

-28.2
207.9
» SLXP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SLXP Guru Trades in Q1 2014

Andreas Halvorsen 1,551,766 sh (New)
Joel Greenblatt 307,445 sh (New)
Paul Tudor Jones 7,400 sh (+131.25%)
Pioneer Investments 450,432 sh (+9.74%)
Vanguard Health Care Fund 2,032,845 sh (-5.36%)
Jim Simons 90,134 sh (-66.43%)
Steven Cohen 7,830 sh (-92%)
» More
Q2 2014

SLXP Guru Trades in Q2 2014

Jim Simons 257,819 sh (+186.04%)
Andreas Halvorsen 2,889,303 sh (+86.19%)
Steven Cohen 527,800 sh (unchged)
Joel Greenblatt Sold Out
Pioneer Investments 417,255 sh (-7.37%)
Vanguard Health Care Fund 1,824,545 sh (-10.25%)
Paul Tudor Jones 1,800 sh (-75.68%)
» More
Q3 2014

SLXP Guru Trades in Q3 2014

Paul Tudor Jones 12,629 sh (+601.61%)
Pioneer Investments 374,220 sh (unchged)
Andreas Halvorsen 2,719,538 sh (-5.88%)
Vanguard Health Care Fund 1,538,045 sh (-15.7%)
Steven Cohen 150,000 sh (-71.58%)
Jim Simons 44,525 sh (-82.73%)
» More
Q4 2014

SLXP Guru Trades in Q4 2014

Louis Moore Bacon 10,000 sh (New)
John Paulson 5,806,000 sh (New)
Jana Partners 1,120,921 sh (New)
George Soros 491,531 sh (New)
Paul Tudor Jones 50,400 sh (+299.08%)
Steven Cohen 502,500 sh (+235%)
Jana Partners 738,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Jim Simons 41,419 sh (-6.98%)
Andreas Halvorsen 1,738,104 sh (-36.09%)
Pioneer Investments 167,884 sh (-55.14%)
» More
» Details

Insider Trades

Latest Guru Trades with SLXP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-12-31 New Buy3.4%$91.47 - $152.87 $ 157.231%5806000
George Soros 2014-12-31 New Buy0.62%$91.47 - $152.87 $ 157.231%491531
Andreas Halvorsen 2014-12-31 Reduce -36.09%0.61%$91.47 - $152.87 $ 157.231%1738104
Vanguard Health Care Fund 2014-12-31 Sold Out 0.61%$91.47 - $152.87 $ 157.230%0
Andreas Halvorsen 2014-06-30 Add 86.19%0.74%$97.7 - $125.07 $ 157.242%2889303
Joel Greenblatt 2014-06-30 Sold Out 0.48%$97.7 - $125.07 $ 157.242%0
Andreas Halvorsen 2014-03-31 New Buy0.67%$88.8 - $114.64 $ 157.254%1551766
Joel Greenblatt 2014-03-31 New Buy0.48%$88.8 - $114.64 $ 157.254%307445
Joel Greenblatt 2013-09-30 Sold Out 0.36%$65.73 - $75.54 $ 157.2128%0
Joel Greenblatt 2013-06-30 New Buy0.36%$47.72 - $66.83 $ 157.2175%127495
Joel Greenblatt 2013-03-31 Sold Out 0.15%$40.472 - $51.37 $ 157.2228%0
Vanguard Health Care Fund 2013-03-31 Add 22.44%0.08%$40.472 - $51.37 $ 157.2228%2147945
NWQ Managers 2012-12-31 Sold Out 0.17%$37.97 - $42.9 $ 157.2285%0
Joel Greenblatt 2012-12-31 Add 75.81%0.06%$37.97 - $42.9 $ 157.2285%63399
Joel Greenblatt 2012-09-30 New Buy0.1%$41.92 - $55.65 $ 157.2231%36061
NWQ Managers 2012-03-31 Reduce -40.33%0.14%$45.72 - $53.75 $ 157.2241%656533
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Salix Pharmaceuticals Ltd

John Paulson's Top Buys
John Paulson (Trades, Portfolio) of Paulson & Co added new positions to his portfolio of 63 stocks with a value of $19.362 billion and a quarter over quarter turnover rate of 11%. Read more...
John Paulson Chooses Energy, Semiconductor and Drug Stocks in Q4
John Paulson (Trades, Portfolio) made a record Wall Street $5 billion payday in 2010 but has had some tough years since then. Read more...

Ratios

vs
industry
vs
history
Forward P/E 19.08
SLXP's Forward P/E is ranked higher than
88% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. SLXP: 19.08 )
N/A
P/B 18.96
SLXP's P/B is ranked higher than
50% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. SLXP: 18.96 )
SLXP' s 10-Year P/B Range
Min: 1.01   Max: 19.81
Current: 18.96

1.01
19.81
P/S 7.66
SLXP's P/S is ranked higher than
64% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. SLXP: 7.66 )
SLXP' s 10-Year P/S Range
Min: 1.28   Max: 12.23
Current: 7.66

1.28
12.23
PFCF 66.05
SLXP's PFCF is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SLXP: 66.05 )
SLXP' s 10-Year PFCF Range
Min: 5.08   Max: 371
Current: 66.05

5.08
371
POCF 60.00
SLXP's POCF is ranked higher than
73% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. SLXP: 60.00 )
SLXP' s 10-Year POCF Range
Min: 3.99   Max: 234.25
Current: 60

3.99
234.25
EV-to-EBIT 464.87
SLXP's EV-to-EBIT is ranked higher than
65% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. SLXP: 464.87 )
SLXP' s 10-Year EV-to-EBIT Range
Min: -1044.1   Max: 481.4
Current: 464.87

-1044.1
481.4
Shiller P/E 1040.53
SLXP's Shiller P/E is ranked higher than
73% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 103.75 vs. SLXP: 1040.53 )
SLXP' s 10-Year Shiller P/E Range
Min: 240.14   Max: 4937
Current: 1040.53

240.14
4937
Current Ratio 0.94
SLXP's Current Ratio is ranked lower than
51% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. SLXP: 0.94 )
SLXP' s 10-Year Current Ratio Range
Min: 0.94   Max: 8.65
Current: 0.94

0.94
8.65
Quick Ratio 0.84
SLXP's Quick Ratio is ranked higher than
52% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. SLXP: 0.84 )
SLXP' s 10-Year Quick Ratio Range
Min: 0.84   Max: 7.92
Current: 0.84

0.84
7.92
Days Inventory 132.15
SLXP's Days Inventory is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. SLXP: 132.15 )
SLXP' s 10-Year Days Inventory Range
Min: 107.26   Max: 367.23
Current: 132.15

107.26
367.23
Days Sales Outstanding 138.36
SLXP's Days Sales Outstanding is ranked higher than
64% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. SLXP: 138.36 )
SLXP' s 10-Year Days Sales Outstanding Range
Min: 23.53   Max: 154.51
Current: 138.36

23.53
154.51

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 7.44
SLXP's Price/DCF (Projected) is ranked higher than
77% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.24 vs. SLXP: 7.44 )
SLXP' s 10-Year Price/DCF (Projected) Range
Min: 2.38   Max: 76.06
Current: 7.44

2.38
76.06
Price/Median PS Value 1.53
SLXP's Price/Median PS Value is ranked higher than
67% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. SLXP: 1.53 )
SLXP' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 3.89
Current: 1.53

0.29
3.89
Earnings Yield (Greenblatt) 0.20
SLXP's Earnings Yield (Greenblatt) is ranked higher than
64% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SLXP: 0.20 )
SLXP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 9.7
Current: 0.2

0.2
9.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:XP2.Germany,
Salix Pharmaceuticals Ltd is a Delaware corporation incorporated on December 1993. The Company is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract. The Companys search and development efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an existing base of safety and efficacy data. Its products include APRISO, the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Another product, COLAZAL, treats mildly to moderately active ulcerative colitis, a form of inflammatory bowel disease. XIFAXAN is a nonsystemic antibiotic that treats travelers' diarrhea caused by noninvasive E. coli. PEPCID treats active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD). OsmoPrep consists of a series of pills taken with the clear liquid. MoviPrep is a tolerable, lowvolume liquid bowel prep with the effectiveness of highvolume prep. VISICOL, the precursor to OsmoPrep, this colonoscopy preparation also features a regimen of tablets taken with any clear liquid. AnusolHC and PROCTOCORT provide soothing relief from anal itching, burning, and inflammation. AZASAN prevents rejection of kidney transplant and provides therapy for the management of severe active rheumatoid arthritis. Diuril treats high blood pressure and is an adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. The Company mainly sells its products to pharmaceutical wholesalers. The Company uses third party manufacturers to produce its products. The research, testing, manufacture, marketing and distribution of drug products are extensively regulated by governmental authorities in the United States and other countries.
» More Articles for SLXP

Headlines

Articles On GuruFocus.com
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
John Paulson's Top Buys Feb 21 2015 
John Paulson Chooses Energy, Semiconductor and Drug Stocks in Q4 Feb 19 2015 
Fourth-Quarter Acquisitions Rearrange Jana Partners’ Portfolio Feb 18 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceu Dec 12 2014 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
Joel Greenblatt's Gotham Capital Top 5 New Stocks May 16 2014 

More From Our Partners
Stock Market News for February 24, 2015 - Market News Feb 24 2015 - ZACKS

More From Other Websites
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix... Feb 28 2015
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events Feb 27 2015
The Salix–Valeant merger: Basics of Salix Pharmaceuticals Feb 27 2015
Rationale of the Salix–Valeant merger Feb 27 2015
Salix Pharmaceuticals, Ltd. Stockholders Encouraged to Contact Securities Law Firm about Takeover Feb 27 2015
Compelling Financial Benefit in Valeant's Latest Buy Feb 27 2015
Basics of the Salix–Valeant merger transaction Feb 26 2015
SALIX PHARMACEUTICALS, LTD. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of... Feb 26 2015
JANA opens new position in Salix Pharmaceuticals Feb 26 2015
The Salix–Valeant merger will follow a cash tender timeline Feb 26 2015
Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point Feb 26 2015
Salix Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 1.5%... Feb 26 2015
Salix Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 2.75%... Feb 25 2015
Salix Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 2.75%... Feb 25 2015
Salix Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 1.5%... Feb 25 2015
Lifshitz & Miller Law Firm Announces Investigation of Bridgepoint Education, Inc., Globe Specialty... Feb 25 2015
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Feb 25 2015
Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash Feb 25 2015
UPDATE - INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors... Feb 24 2015
Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of Salix Pharmaceuticals, Ltd. Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK